Premium
Therapy for isocitrate dehydrogenase 2 ( IDH2 ) R172 ‐mutant acute myeloid leukaemia
Author(s) -
Linch David C.,
Hills Robert K.,
Burnett Alan K.,
Russell Nigel,
Gale Rosemary E.
Publication year - 2022
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17981
Subject(s) - idh2 , isocitrate dehydrogenase , idh1 , medicine , myeloid leukaemia , oncology , cohort , myeloid leukemia , mutant , immunology , biology , enzyme , genetics , gene , biochemistry
Summary Although we earlier reported a very poor outcome for younger adult patients with isocitrate dehydrogenase 2 ( IDH2 ) R172 ‐mutated acute myeloid leukaemia (AML) entered into UK trials compared to IDH2 WT and IDH2 R140 ‐mutated patients, this was not corroborated by a study from the German‐Austrian AML Study Group. We have therefore investigated a later cohort of IDH2 ‐mutated patients to identify any changes in outcome and whether this could inform the optimal treatment for IDH2 R172 AML. We found an improved outcome for IDH2 R172 ‐mutated AML in the later trials and the data suggests that this may be due to the increased use of allogeneic transplantation to consolidate first remission.